Know any stock in seconds.

Name: AbbVie Inc. (ABBV) — Business Quality Analysis
Creator: Plainview
License: https://plainviewintel.com/terms

Type a ticker — we pressure-test it against live facts, filings, and sentiment.

AbbVie Inc. (ABBV) stock analysis

AbbVie Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 7.3/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, AbbVie Inc. shows trailing revenue of $64.39B, a 72.8% gross margin, net debt of $57.67B, EPS of 3.57, valued at about 7.1x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

Current Price: $257.12
YTD Return: +12.1%
Revenue TTM: $64.39B
Revenue Trend: YoY +7.7%
Gross Margin: 72.8%
Net Cash: $-57.67B
EPS: 3.57
P/S Ratio: 7.1x

Compare: ABBV vs UNH · ABBV vs JNJ · ABBV vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, TMO

🎯 Today's top pickstoday's moversSAMPLE · live scan coming soon

RKLB▲ 6.1%

Neutron test-fire cleared overnight — launch cadence story intact.

HIMS▲ 4.5%

Subscriber beat leaked pre-market — telehealth re-rate building.

NVDA▲ 3.8%

Asia AI-capex headlines overnight — momentum into the open.

👁 Watching · popular

RDW at buy-zone$14.20

ASTS spectrum catalyst▲ 5.2%

MP rare-earth tailwind$31.40

SOFI credit turning$9.80

IONQ quantum momentum▼ 1.4%

🔍 Candidates · early

OKLOACHRTEMRXRXSMRJOBYCLSKTMCSERVBTDR

Got holdings? Sign in to track your portfolio, theses, and catalysts.